Postmenopausal Estrogen, Cancer and Other Consideration
作者:
BarrettElizabeth,
期刊:
Women&Health
(Taylor Available online 1987)
卷期:
Volume 11,
issue 3-4
页码: 179-195
ISSN:0363-0242
年代: 1987
DOI:10.1300/J013v11n03_13
出版商: Taylor&Francis Group
数据来源: Taylor
摘要:
The female hormone estrogen is widely prescribed to postmenopausal women. Its major documented benefit is prevention of bone mineral loss, which is a major risk factor for fracture in the elderly. Its clearly documented risk is promotion of cancer of the endometrium. There is a growing body of data that suggests that postmenopausal estrogen therapy reduces the risk of cardiovascular disease. This benefit, if real, may be lost when a cyclic progeslin is added to reduce the risk of cancer. Further studies are needed to provide a firmer basis for balancing these risks and benefits.8%2F200
点击下载:
PDF (477KB)
返 回